| Product Name | YK11 |
| Synonym | (17-alpha,20E)17,20-[(1-methoxyethylidene)bis(oxy)] 3-oxo-19-norpregna-4,20-diene 21-carboxylic acid methyl ester |
| CAS | 431579-34-9 |
| Assay | 99% |
| Appearance | White crystalline powder |
| Packing | 1kg net/foil bag, 5kg/drum. |
| Standard | Enterprise Standard |
| Storage | Shading , Confined Preservation |
| Usage | Fat loss; muscle growth |
| Molecular Fomular | C152H252N44O42 |
| Molecular Weight | 3367.2 |
| PRODUCT NAME | YK11 | ||
| CAS no. | 1370003-76-1 | Quantity | 18.5kg |
| Storage | In an airtight container, protected from light. | ||
| Items of analysis | Specification | Results | |
| Description | White to off-white powder | Complies | |
| 1HNMR | Conforms to structure | Complies | |
| Residual on ignition | ≤0.5% | 0.08 | |
| Loss on drying | ≤2.0% | 0.72 | |
| Assay | ≥99.0% | 99.62 | |
| Name | NO. | Usage |
| RAD140 | 1182367-47-0 | New generation for gaining mass and cutting edges |
| Andarine(S4) | 401900-40-0 | partial agonist, intended mainly for treatment of benign prostatic hypertrophy |
| MK-677 | 15972-10-0 | A growth hormone secretagogue, treatment of obesity, a promising therapy for the treatment of frailty in the elderly |
| LGD-4033 | 1165910-22-4 | pharmacological profile similar to that of enobosarm, Ostarine,MK-2866 |
| GW1516 | 317318-70-0 | For obesity, diabetes, dyslipidemia and cardiovascular disease |
| MK2866 | 841205-47-8 | medical prescription for prevention of cachexia, atrophy, and sarcopenia and for Hormone or Testoserone Replacement Therapy. |
| SR9009 | 1379686-30-2 | under development at The Scripps Research Institute (TSRI), increases the level of metabolic activity in skeletal muscles of mice |
| Aicar | 2627-69-2 | acts by entering nucleoside pools, significantly increasing levels of adenosine during periods of ATP breakdown |
| YK11 | 431579-34-9 | YK11: a SARM and myostatin inhibitor in one |